Home » Introgen Reports Additional Efficacy Data for Cancer Drug Advexin
Introgen Reports Additional Efficacy Data for Cancer Drug Advexin
Introgen Therapeutics announced that additional efficacy data Phase 3 clinical trial of Advexin in head and neck cancer patients achieved statistically significant benefits in tumor response rate, six-month survival, and overall survival.
RTTNews
RTTNews
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May